Clinical Trial – Raising awareness of Alicaforsen to treat pouchitis

Posted 31 October 2017 in

This trial is open to pouchitis patients currently in flare that have failed to respond to one or more courses of antibiotics, or are contra-indicated to antibiotics.

Atlantic Healthcare enrols 110th patient to its Phase 3 trial of alicaforsen to treat pouchitis.

Atlantic Healthcare plc (“Atlantic Healthcare”), an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal (GI) disorders, provides an update that it has recruited its 110th patient, out of a total of 138, to its Phase 3 trial of alicaforsen to treat pouchitis, a rare and serious form of inflammatory bowel disease (IBD) for which there is no approved therapy and limited treatment options.

More information from Atlantic Healthcare website